Eyepoint Pharmaceuticals Inc (EYPT) — Net Asset Quality Index
Eyepoint Pharmaceuticals Inc (EYPT) has a Net Asset Quality Index of 79.5% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $251.69 Million minus total liabilities of $51.51 Million yields net assets of $200.18 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check asset resilience ratio of Eyepoint Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Eyepoint Pharmaceuticals Inc Net Asset Quality Index Over Time (2000–2024)
This chart shows how Eyepoint Pharmaceuticals Inc's Net Asset Quality Index has evolved across 24 annual periods from 2000 to 2024. As of September 2025, the index stands at 79.5%, representing net assets of $200.18 Million against total assets of $251.69 Million USD. See Eyepoint Pharmaceuticals Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Eyepoint Pharmaceuticals Inc (2000–2024)
The table below presents the year-by-year Net Asset Quality Index for Eyepoint Pharmaceuticals Inc from 2000 to 2024, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Eyepoint Pharmaceuticals Inc.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 80.4% | $336.50 Million | $418.46 Million | $81.96 Million | ▲ +5.4 pp |
| 2023 | 75.0% | $266.32 Million | $355.18 Million | $88.86 Million | ▲ +21.5 pp |
| 2022 | 53.4% | $96.37 Million | $180.36 Million | $83.99 Million | ▼ -16.6 pp |
| 2021 | 70.0% | $184.38 Million | $263.37 Million | $78.99 Million | ▲ +49.8 pp |
| 2020 | 20.2% | $18.54 Million | $91.72 Million | $73.18 Million | ▲ +8.8 pp |
| 2019 | 11.4% | $8.33 Million | $72.97 Million | $64.64 Million | ▼ -4.9 pp |
| 2018 | 16.3% | $11.69 Million | $71.67 Million | $59.98 Million | ▼ -55.1 pp |
| 2017 | 71.4% | $13.34 Million | $18.68 Million | $5.34 Million | ▲ +5.4 pp |
| 2016 | 66.0% | $20.88 Million | $31.62 Million | $10.74 Million | ▼ -6.2 pp |
| 2015 | 72.2% | $23.37 Million | $32.37 Million | $9.00 Million | ▲ +6.4 pp |
| 2014 | 65.8% | $14.92 Million | $22.67 Million | $7.75 Million | ▲ +18.4 pp |
| 2013 | 47.4% | $7.70 Million | $16.25 Million | $8.55 Million | ▼ -18.8 pp |
| 2012 | 66.2% | $13.64 Million | $20.60 Million | $6.96 Million | ▼ -13.2 pp |
| 2011 | 79.5% | $37.43 Million | $47.11 Million | $9.68 Million | ▲ +2.6 pp |
| 2010 | 76.8% | $33.04 Million | $43.01 Million | $9.97 Million | ▲ +13.4 pp |
| 2009 | 63.4% | $23.54 Million | $37.10 Million | $13.56 Million | ▲ +7.9 pp |
| 2008 | 55.5% | $21.79 Million | $39.23 Million | $17.44 Million | ▼ -21.0 pp |
| 2007 | 76.5% | $65.91 Million | $86.12 Million | $20.21 Million | ▲ +8.7 pp |
| 2006 | 67.8% | $66.20 Million | $97.60 Million | $31.40 Million | ▼ -29.7 pp |
| 2005 | 97.5% | $60.74 Million | $62.30 Million | $1.56 Million | ▲ +0.0 pp |
| 2004 | 97.5% | $60.74 Million | $62.30 Million | $1.56 Million | ▲ +2.3 pp |
| 2003 | 95.2% | $26.70 Million | $28.05 Million | $1.35 Million | ▲ +7.4 pp |
| 2002 | 87.8% | $4.23 Million | $4.82 Million | $588.38K | ▼ -9.1 pp |
| 2000 | 96.9% | $4.57 Million | $4.72 Million | $145.74K | — |